The antibody-based drug developer, which counts WuXi AppTec, Fosun, Sinopharm and Humanwell as investors, has floated in a $126m offering.
Ambrx Biopharma, a US-headquartered immuno-oncology drug developer backed by corporates WuXi AppTec, Fosun, Sinopharm and Humanwell, has raised $126m in an initial public offering on the New York Stock Exchange.
The company priced 7 million American depositary shares (ADS), each representing seven ordinary shares, at $18 each, at the midpoint of the offering’s $17 to $19 range.
Founded in 2003, Ambrx is focused on developing antibody drug conjugates (ADCs) to treatmultiple types of cancer. It is leveraging a genetic…
